Unbound MEDLINE

[Myasthenia-like syndrome induced by cibenzoline overdose in a patient with chronic kidney disease] Nippon Jinzo Gakkai shi [Nippon Jinzo Gakkai Shi] Journal article

 
Title[Myasthenia-like syndrome induced by cibenzoline overdose in a patient with chronic kidney disease]
Author(s)Kawasaki H, Yahata K, Okamoto C, Imamaki H, Seta K, Sugawara A 
InstitutionDepartment of Nephrology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
SourceNippon Jinzo Gakkai Shi 2008; 50(7):942-7.
MeSHAged
Anti-Arrhythmia Agents
Chronic Disease
Female
Humans
Imidazoles
Kidney Diseases
Myasthenia Gravis
Overdose
AbstractA female in her late 60s with chronic kidney disease was admitted to the emergency department with complaints of dizziness four days prior to hospitalization. Cibenzoline (300 mg/day) was administered for atrial fibrillation, which was detected in an electrocardiogram. After three days, she experienced blepharoptosis and was admitted for suspected myasthenia gravis. However, the anti-acetylcholine receptor antibody and edrophonium tests were negative. On day four after hospitalization, she suffered from pneumonia with pleural effusion and she was put on a respirator for four days. From day 16 after hospitalization, she had diarrhea and her renal function worsened. At the same time, a gradual aggravation of right blepharoptosis, dull headache, weakness and difficulty in chewing were noted. She experienced dyspnea on day 31 after hospitalization. Chest X-ray film did not show a pneumonia shadow or pleural effusion, and arterial blood gases revealed hypercapnia; she was diagnosed as having CO2 narcosis due to respiratory muscle fatigue and was put on a respirator again. Myasthenia-like syndrome was suspected because of a probable overdose of cibenzoline and administration of cibenzoline was withdrawn. Her condition improved and she was taken off the respirator on day 35 after hospitalization. Repetitive stimulation of 5 Hz was applied to her right facial nerve along with evoked electromyogram(EMG) on days 2 and 11 after discontinuing cibenzoline. On day 2, the EMG showed a waning phenomenon, whereas no such phenomenon was seen on day 11. The blood concentration of cibenzoline immediately after withdrawal was extremely high (2448 ng/mL). When this drug is administered to a patient with chronic kidney disease, attention must be paid to the indication, dose, and manifestation of the possible side effects.
Languagejpn
Pub Type(s)Case Reports
English Abstract
Journal Article
PubMed ID19069153
  
Advertise on this site.